Clinical Trial

A Study of LM-108 in Combination With Toripalimab in Subjects With Advanced Solid Tumours

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Based on overall response rate (ORR) as assessed by the Independent Review Committee (IRC) against the Response Evaluation Criteria in Solid Tumors (RECIST v1.1) criteria for Solid Tumor Efficacy, To evaluate the efficacy of LM-108 in combination with Toripalimab in patients with advanced malignant solid tumours with unresectable or metastatic MSI-H/dMMR who have failed previous anti-PD-1 /PD-L1 therapy.
Trial Details
NCT Number NCT06873854
Lead Sponsor LaNova Medicines Limited
Collaborators: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Conditions Advanced Solid Tumor
Enrollment 84 participants
Start Date 2025-03-26
Primary Completion 2028-01-26 (estimated)
Study Completion 2030-01-26 (estimated)
Updated on ClinicalTrials.gov 2025-03-13